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Summary We have carried out a prospective study on the impact of computed tomography (CT) and
ultrasonography (US) on the management of patients with carcinoma of the ovary. Seventy-eight CT and 88
US scans were performed on 94 patients. Clinicians decided patient management prospectively at the time the
CT and/or US was ordered. Clinical assessment differed from the result obtained by CT or US in 45% of
cases (35/78 and 40/88, respectively). CT and US altered patient management in only a minority of cases
(14/78, 18% and 9/88, 10% respectively). Even when the scan and clinical assessments differed, management
was only altered on 14/35 (40%) occasions after CT and on 9/40 (23%) occasions after US, a difference which
was not significant. In patients with clinically undetectable disease, management was altered by CT on 17% of
occasions and by US on 10%. We conclude that in patients with carcinoma of the ovary CT and US alters
patient management in a minority of cases. In view of current financial restrictions in health care, clinicians
should be more selective in the use of these imaging techniques. Furthermore, we recommend that similar
prospective studies are performed for other clinical situations.
Clinical and radiological assessment of patients with car-
cinoma of the ovary is notoriously difficult as evidenced by
the current practice of performing second-look laparotomies
to assess response to post-surgical treatments such as
chemotherapy and radiotherapy. When patients are assessed
non-surgically the two major imaging techniques used are
computerised axial tomography (CT) and ultrasonography
(US). US is effective in assessing disease in the pelvis, upper
abdomen and liver and is a very sensitive method of diagnos-
ing the presence of ascites but it is not a good method of
diagnosing disease in the omentum, mesentery or bowel
(Khan et al., 1986). CT is probably more accurate in diag-
nosing the presence of disease in certain areas such as
paraaortic lymph nodes (Kerr-Wilson et al., 1984; Wicks et
al., 1984; Sonnendecker & Butterworth, 1985; Sommer et al.,
1982), the omentum, mesentery and sub-diaphragmatic
regions (Sommer et al., 1982; Levitt et al., 1978; Bernardino
et al., 1979; Whitley et al., 1981; Johnson et al., 1983).
Overall, studies have shown CT and US to be of similar
usefulness (Kerr-Wilson et al., 1984; Sommer et al., 1982;
Nash et al., 1979; Paling & Shawker, 1981) and most studies
agree that neither technique can replace second-look
laparotomy (Sonnendecker & Butterworth, 1985; Sommer et
al., 1982; Johnson et al., 1983; Stern et al., 1981). US has
certain advantages compared to CT, in that it is less expen-
sive, does not involve radiation, no contrast media are used
and it is less traumatic for the patient.
What then is the role of either CT or US scanning in the
management of patients with carcinoma of the ovary? In
particular, does either of these techniques result in a change
in the patients' management? One large prospective study
(Wittenburg et al., 1980), involving a diagnostically very
heterogeneous group of patients undergoing CT of a variety
of areas (chest, abdomen, pelvis and bone), suggested that
CT contributed to a change of therapy in 14% of cases.
However, in only 5% was the CT scan considered by the
ordering physician to have been 'very important compared to
other factors.' It has been claimed that in patients suffering
from carcinoma of the ovary CT provides information that is
useful in patient management in 59 - 83% of cases (Whitley
et al., 1981; Johnson et al., 1983). Whitley et al. (1981)
claimed that clinical decisions were based on CT alone in
43% of scans performed but this assessment was made ret-
rospectively without the clinician indicating a proposed man-
agement policy before the scan result was known. Johnson et
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al., (1983) failed to provide any detail of how patient man-
agement was altered.
We report a prospective study in patients with carcinoma
of the ovary that specifically recorded the number of times a
CT of US scan altered patient management.
Materials and methods
Patients
Ninety-four patients with carcinoma of the ovary who were
being followed up at the Royal Marsden Hospital, London,
between September 1986 and May 1987 had their disease
assessed simultaneously by clinical examination and CT of
the abdomen and pelvis and/or US of the abdomen and
pelvis on 120 occasions.
Sixty-two patients had a CT scan on 78 occasions, 71
patients had an US scan on 88 occasions. Thirty-nine of
these patients had both a CT scan and an US scan within
two weeks ofeach other on 46 occasions. These patients were
on therapeutic protocols that required both investigations to
be performed.
Criteriafor entry to study
Patients with a histological diagnosis of epithelial carcinoma
of the ovary were included in the study irrespective of wheth-
er or not they were on treatment. Patients were staged ac-
cording to the International Federation of Gynaecology and
Obstetrics (FIGO). The stage of the patients entered into the
study is shown for each scan performed in Table I. All
patients had a previous CT and/or US scan. Patients who
were being staged at initial presentation either pre- or post-
surgery were excluded.
Table I FIGO stage of patients
No. ofscans performed
CT US
Stage I 4 8
Stage II 11 10
Stage III 28 32
Stage IV 19 16
Recurrence 13 17
Not known 3 5
Total 78 88
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Clinical assessment
Patients were assessed by three medical oncolgists
experienced in the management of patients with
gynaecological malignancies. At the time the CT or US scan
was ordered the clinician filled in a questionnaire (Table II)
which was designed to allocate patients into a group accord-
ing to the reason for the scan, the patient's clinical disease
status and intended management. As shown in Table II,
there were three reasons why patients were scanned. Patients
who were scanned 'routinely' were off all treatment and there
was no suspicion of recurrence but a CT or US scan was
done as part of their 'routine follow-up'.
The clinical assessment of the patient was made by taking
a history and by careful clinical examination. The clinician
then had to indicate on the questionnaire the disease status
of the patient (Table II). The criteria for the disease status
was defined according to standard criteria (Miller et al.,
1981). Finally, the clinician had to indicate how he would
manage the patient if no CT or US was available (continue
with treatment, continue with no treatment, change treatment
or stop treatment) (Table II).
A correlation between the reason a scan was requested and
the patients' clinical status and proposed management is
shown in Tables III and IV respectively.
Table 11 The questionnaire filled in by the
clinician at the time the scan was requested but
after the patient had been assessed clinically
CT scan
US scan
Reasonfor scan
Routine follow-up
Suspicion of recurrence
Measurement of treatment response
Clinical impression
No disease (ND)
Disease present but not evaluable (NE)
Stable disease (SD)
Progressive disease (PD)
Partial response (PR)
Complete response (CR)
Clinical action
Continue with treatment
Continue with no treatment
Change treatment
Stop treatment
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Table III Correlation between reason for scan and the clinical
impression of the patients' disease status
Reasonfor scan
Measuring
Diagnosis of treatment Routine
relapse response follow-up
Clinical assessment CT US CT US CT US
ND 3 16 4 3 8 16
NE 2 3 16 10 2 3
SD 0 1 15 13 0 1
PD 12 0 3 5 0 0
PR 0 0 12 10 0 0
CR 0 0 1 2 0 0
Total 17 20 51 43 10 20
ND, = no disease; NE, =disease present but not evaluable; SD, =
stable disease; PD, = progressive disease; PR, = partial response; CR,
= complete response.
Table IV Correlation between reason for scan and the clinical
action planned at the time it was requested
Measuring
Diagnosis treatment Routine
ofrelapse response follow-up
CT US CT US CT US
Continue with treatment 1 3 28 24 0 0
Continue with no treat- 3 7 0 0 9 19
ment
Change treatment 13 13 8 8 1 1
Stop treatment 0 2 15 11 0 0
Total 17 25 51 43 10 20
CT/US assessment
CT scans were performed using a Siemens Somaton DR2
scanner. Patients were given 500ml of 1.5% Gastrografin
orally 90 min and 45 min before the scan and 100 ml of 1.5%
Gastrografin rectally. Intravenous contrast was not given
routinely. Eight millimetre wide sections were then obtained
at 12 mm intervals throughout the abdomen and 4 mm wide
sections at 5 mm intervals in the pelvis. The duration of each
section was 4s. US scans were performed using a GE RT
3000 real-time scanner. Patients were prepared with a full
bladder. Multiple sections of the abdomen and pelvis were
obtained in transverse and sagittal planes.
Radiologists experienced in CT and US of patients with
gynaecological malignancies interpreted the scans. Scan
requests contained usual clinical details but the reporting
radiologist did not know the intended management of the
patient. The radiologist indicated on a separate form whether
there was no response to treatment, measurable disease had
increased or decreased, new disease was present, a complete
response had been achieved, or whether no disease was pres-
ent on two consecutive scans, the second of which being the
one under current investigation.
Clinical/scan comparison
Three months after the scan had been performed the findings
of the CT and US scans were compared to the clinical
impression. This time interval allowed complete independence
between the study and the routine management of the
patients. The hospital notes were examined to assess whether
the original decision with regard to the patient's management
(continue with treatment, continue with no treatment, change
treatment or stop treatment) was altered as a result of the
scan report. Statistical comparisons were made using the x2
test with Yates' correction unless otherwise specified, when
Fisher's exact test (FET) was used.
Results
Overall
Clinical assessment ofpatient's disease status was the same as
the CT and US reports on 55% of occasions (Table V).
There was no significant difference between the number of
times CT altered treatment (18%) as compared to US (10%).
When clinical evaluation and the CT report differed, patient
management was altered on 40% (14/35) of occasions and on
22% (9/40) of occasions when the clinical impression and the
US scan result differed, but this was not statistically sig-
nificant.
On 46 occasions CT and US scans were performed within
two weeks of each other and thus the two imaging techniques
could be compared to the same clinical assessment. There
were no significant differences between the number of times
scan results differed from the clinical assessment or the
number of times patients' management was altered.CT AND US IN OVARIAN CANCER 753
Table V Correlation between clinical and CT/US assessment
Imaging technique
CT US
Clinical scan assessment
Same 43/78 (55%) 48/88 (55%)
Different 35/78 (45%) 40/88 (45%)
Patient management 14/78 (18%) 9/88 (10%)
altered
Disease status
Patients in whom the CT or US scan result differed from the
clinical assessment were analysed according to disease status
as defined by that clinical impression (Table VI). As might be
expected, on 21/35 (60%) occasions patients with clinically
undetectable disease (ND or NE) had a CT scan that did not
correlate with the clinical assessment, whereas on only 14/43
(33%) occasions did patients with clinically detectable disease
(5/15 SD; 3/15 PD; 6/13 PR + CR) have a CT report that
did not correlate with the clinical assessment and this dif-
ference was significant (21/35 vs 14/43, P = 0.03). Never-
theless, the number of occasions when treatment was altered
as a result of a CT scan was remarkably constant (13-23%,
Table VI). There was no significant differences between any
of the disease status categories in patients who had a US
scan (Table VI). Hbwever, when a direct comparison was
made between CT and US for patients with undetectable
disease there were no significant differences (scan results and
clinical impression differed on 60% of occasions for CT and
49% of occasions for US).
Management of patients with undetectable disease was
altered after CT and US on a similar number of occasions
(Table VI). Furthermore, within the subgroup of patients
with undetectable disease who had CT and US performed at
the same time scan results and clinical impression differed on
exactly the same number of occasions (72%, data not
shown).
FIGO staging
The number of occasions CT or US differed from the clinical
impression was analysed according to the FIGO stage of the
patients. The only significant difference between CT and US
was found in patients with stage IV disease where US dif-
fered from the clinical impression more often than CT
(P = 0.04, FET) but patient management was not altered
more frequently after a US scan.
Reasonsfor scanning
Table VII shows the impact of imaging techniques on the
clinical management of patients analysed according to the
reason the scan was ordered, i.e. suspicion of recurrence,
assessment of response to treatment and 'routine follow-up'.
There were no significant differences between CT and US
and the number of times the scan results differed from the
clinical asses§ment. The management of patients was altered
as a result of CT on 29% of occasions when the patient was
thought to have relapsed and on 18% of occasions when the
scan was performed to measure treatment response. On no
occasion was there any alteration in the patients' manage-
ment when a CT scan was performed for 'routine' purposes
(Table VII). However, none of these differences were statis-
tically significant and similar results were obtained for
patients undergoing US (Table VII).
Discussion
This study shows that in patients with carcinoma of the
ovary there are no significant differences between the results
obtained from CT and US scanning when each is compared
separately to clinical evaluation; other authors have reported
similar results (Kerr-Wilson et al., 1984; Sommer et al., 1982;
Nash et al., 1979; Paling & Shawker, 1981). We have found
that the alteration of a patient's management is not in-
fluenced by the imaging technique used, only 18% of CT
Table VI Correlation between disease status and scan/clinical
assessment
CT scan US scan
Scan/clinical Scan/clinical
assessment Patient assessment Patient
Clinical management management
assessment n Different (%) altered (%) n Different (%) altered (%)
Non-detectable
disease 35 21 (60) 65 (17) 39 19 (49) 4 (10)
(ND and NE)
Stable disease 15 5 (33) 2 (13) 14 7 (50) 2 (14)
Progressive
disease 15 3 (20) 3 (20) 23 9 (39) 3 (13)
Responding
disease 13 6 (46) 3 (23) 12 5 (42) 0 (0)
(PR and CR)
Table VII Correlation between reason for scan/clinical assessment
Clinical scan
assessment Patient
management
Reasonfor scan Scan n Same (%) Different (%) altered (%)
Diagnosis of CT 17 10 (59) 7 (41) 5 (29)
relapse US 25 14 (56) 11 (44) 4 (16)
Measuring treatment CT 51 25 (49) 26 (51) 9 (18)
response US 43 20 (47) 23 (53) 3 ( 7)
Routine follow up CT 10 8 (80) 2 (20) 0 ( 0)
US 20 14 (70) 6 (30) 2 (10)754 M.E. GORE et al.
scans and 10% of US scans altered patient management, a
difference which is not statistically significant. More impor-
tantly, even when the scan result differs from the clinical
impression a patient's treatment is only altered on a minority
of occasions, 40% after CT and 23% after US.
Previous studies in patients with carcinoma of the ovary
that have attempted to quantify the impact of CT on patient
management have done so by asking clinicians retrospectively
whether or not a scan influenced their treatment decisons
(Whitley et al., 1981; Johnson et al., 1983). This same ret-
rospective approach has been used in larger studies on the
efficacy of CT in other patient populations (Wittenberg et
al., 1980; Baker & Way, 1978; Robbins et al., 1978). Our
study is the first time an attempt has been made to evaluate
the impact of CT and US on the management of patients
with carcinoma of the ovary in a prospective manner. The
major differences between this study and all others is that the
clinicians had to record their management decisions prospec-
tively at the time the scan was ordered. In addition, by
allowing a time interval between the scan result and the
analysis of its impact, routine patient management was not
influenced by the study. Further power is lent to this study
by the fact that in 38% of cases both scans were performed
for the same clinical event. This group ofpatients acted as an
internal control for the study in that none of the results for
this sub-group of patients differed from the study results as a
whole.
Our data suggest that the routine performance of CT or
US is not indicated in patients with carcinoma of the ovary
who are off treatment and in whom there is no clinical
suspicion of recurrence. In this study patient management
was only altered on 10% and 0% of occasions when US or
CT respectively were performed as a 'routine'. CT and US
seemed to be valuable in the diagnosis of relapse in that the
scan results and clinical assessment differed on 41% and
44% of occasions respectively. Similar results were obtained
for patients in whom treatment response was being assessed.
There is therefore, a case for patients who are on therapeutic
studies to have a CT or US scan to measure treatment
response if they are not going to undergo second look
laparotomy or laparoscopy. Similarly the diagnosis of relapse
in patients entered into a study should be confirmed by an
imaging technique.
Patients who are not in any form of trial or study should
not automatically undergo imaging since management is
altered in only a minority of patients as a result. It is clear
from our study that clinicians should decide before ordering
a scan how the result will alter patient management. Know-
ing what is going on has been claimed to be valuable, giving
clinicians confidence in patient management (Wittenberg et
al., 1980) but we challenge this concept since our study shows
that even when the scan result and the clinical assessment
differ, patient management is altered in only a minority of
cases. We suggest that similar prospective studies of the
impact of CT and US should be carried out in other clinical
situations, particularly in view of the current situation of
rising costs and shrinking resources.
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